CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Rivanna Medical announced today that it has begun manufacturing its FDA-cleared Accuro™ device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San Diego, Oct. 24-28, 2015.
The Accuro™ device is designed to provide automated 3D navigation to an anatomical target so a clinician may avoid “guessing” where the target is. The initial commercial application of RIVANNA’s Accuro™ platform is designed for guiding clinicians to a first-attempt success in administering spinal anesthesia into the epidural space.
“There are numerous clinical uses for Accuro™, which is designed to be a disruptive, game-changing platform technology,” said John A. Williams, President and CEO. “The Accuro™ platform, based on automated 3D navigation, has an addressable $1+ billion U.S. market today. Because of the considerable unmet clinical need for automated image guidance in general, and in the spinal anesthesia market especially, we are looking forward to launching Accuro™ at the upcoming annual scientific meeting of the ASA in less than three months.”
RIVANNA will be showcasing its Accuro™ device at Booth #4726 during ASA.
About Rivanna Medical
Based in Charlottesville, Virginia, RIVANNA is a privately held medical technology company that is commercializing its initial product, Accuro™, a proprietary and versatile imaging product that is FDA 510(k)-cleared for spinal anesthesia guidance and a variety of additional imaging applications, such as diagnostic imaging of the cardiac and abdominal anatomies.
NOTE: Rivanna Medical’s Accuro™ product is the world’s first ultrasound system designed specifically for spinal anesthesia guidance.